Capricor Therapeutics Inc
NASDAQ:CAPR

Watchlist Manager
Capricor Therapeutics Inc Logo
Capricor Therapeutics Inc
NASDAQ:CAPR
Watchlist
Price: 6.82 USD 4.6% Market Closed
Market Cap: 311.7m USD

Operating Margin
Capricor Therapeutics Inc

-329.9%
Current
-979%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-329.9%
=
Operating Profit
-57.3m
/
Revenue
17.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Capricor Therapeutics Inc
NASDAQ:CAPR
311.5m USD
-330%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
336.6B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
165.8B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
141.4B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.3B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
128.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.9B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Capricor Therapeutics Inc
Glance View

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in Beverly Hills, California and currently employs 48 full-time employees. The company went IPO on 2002-06-04. The firm consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The firm is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.

CAPR Intrinsic Value
33.33 USD
Undervaluation 80%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-329.9%
=
Operating Profit
-57.3m
/
Revenue
17.4m
What is the Operating Margin of Capricor Therapeutics Inc?

Based on Capricor Therapeutics Inc's most recent financial statements, the company has Operating Margin of -329.9%.

Back to Top